[1]于 淙,欧阳天佐,周 培.吡格列酮治疗非酒精性脂肪肝有效性及安全性的Meta分析[J].医学信息,2020,33(13):60-64.[doi:10.3969/j.issn.1006-1959.2020.13.017]
 YU Cong,OUYANG Tian-zuo,ZHOU Pei.Meta-analysis of the Efficacy and Safety of Pioglitazone in the Treatment of Non-alcoholic Fatty Liver[J].Medical Information,2020,33(13):60-64.[doi:10.3969/j.issn.1006-1959.2020.13.017]
点击复制

吡格列酮治疗非酒精性脂肪肝有效性及安全性的Meta分析()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年13期
页码:
60-64
栏目:
论著
出版日期:
2020-07-01

文章信息/Info

Title:
Meta-analysis of the Efficacy and Safety of Pioglitazone in the Treatment of Non-alcoholic Fatty Liver
文章编号:
1006-1959(2020)13-0060-05
作者:
于 淙欧阳天佐周 培
(1.威海市中心医院感染性疾病科,山东 威海 264400;2.西藏民族大学附属医院感染性疾病科,陕西 咸阳 712000)
Author(s):
YU CongOUYANG Tian-zuoZHOU Pei
(1.Department of Infectious Diseases,Weihai Central Hospital,Weihai 264400,Shandong,China;2.Department of Infectious Diseases,the Affiliated Hospital of Tibet Nationalities University,Xianyang 712000,Shaanxi,China)
关键词:
吡格列酮非酒精性脂肪肝不良反应
Keywords:
PioglitazoneNon-alcoholic fatty liverAdverse reactions
分类号:
R575
DOI:
10.3969/j.issn.1006-1959.2020.13.017
文献标志码:
A
摘要:
目的 对吡格列酮治疗非酒精性脂肪肝是否有效及安全进行系统评价。方法 电子检索截至2019年8月之前公开发表在万方数据库、中国期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、中文科技期刊全文数据库(VIP)、PubMed、Cochrane Library的随机对照试验,包括使用任何方案的吡格列酮与安慰剂的非酒精性脂肪肝患者的比较。主要结局包括肝脏病理、肝脏生化、胰岛素抵抗、不良反应。结果 最终纳入10篇文献,共有723例患者。Meta分析结果显示,吡格列酮可以减轻非酒精性脂肪肝患者肝脂肪变性(OR=0.26,95%CI:0.14~0.46)、肝气球样变(OR=0.38,95%CI:0.24~0.60)、肝小叶炎症(OR=0.33,95%CI:0.21~0.50)、肝纤维化(OR=0.57,95%CI:0.37~0.88),改善ALT(MD=10.33,95%CI:3.27~17.38)、AST(MD=9.51,95%CI:3.03~15.99)、空腹血糖(MD=0.47,95%CI:0.20~0.75)、胰岛素抵抗指数(HOMA-IR)(MD=1.17,95%CI:0.82~1.51)等指标,与对照组比较,差异有统计学意义(P<0.05)。结论 吡格列酮可有效治疗非酒精性脂肪肝,尤其在改善肝组织学、肝功能、改善胰岛素抵抗等方面有较为明显优势。不良反应主要为肌肉酸痛,总体不良反应较少且均较轻。
Abstract:
Objective To systematically evaluate whether pioglitazone is effective and safe in the treatment of non-alcoholic fatty liver.Methods Electronic retrieval as of August 2019. Randomized controlled trials published in Wanfang database, Chinese Journal Full-text Database (CNKI), Chinese Biomedical Literature Database (CBM), Chinese Science and Technology Journal Full-text Database (VIP), PubMed, Cochrane Library, Including comparison of pioglitazone with placebo in nonalcoholic fatty liver patients. The main outcomes include liver pathology, liver biochemistry, insulin resistance, and adverse reactions.Results Finally, 10 articles were included, with a total of 723 patients. Meta analysis results showed that pioglitazone can reduce hepatic steatosis (OR=0.26, 95%CI: 0.14~0.46), hepatic balloon-like degeneration (OR=0.38, 95%CI: 0.24~0.60), liver Lobular inflammation (OR=0.33, 95%CI: 0.21~0.50), liver fibrosis (OR=0.57, 95%CI: 0.37~0.88), improve ALT (MD=10.33, 95%CI: 3.27-17.38), AST (MD=9.51, 95%CI: 3.03~15.99), fasting blood glucose (MD=0.47, 95%CI: 0.20~0.75), insulin resistance index (HOMA-IR) (MD=1.17, 95%CI: 0.82~1.51 )and other indicators, compared with the control group, the difference was statistically significant (P<0.05).Conclusion Pioglitazone can effectively treat non-alcoholic fatty liver, especially in improving liver histology, liver function and insulin resistance. The adverse reactions were mainly muscle aches, and the overall adverse reactions were few and mild.

参考文献/References:

[1]Younossi ZM,Koenig AB,Abdelatif D,et al.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes[J].Hepatology,2016,64(1):73-84.[2]Byrne CD,Targher G.NAFLD:a multisystem disease[J].Hepatol,2015,62 (1 Suppl):S47-S64.[3]Shakir AK,Suneja U,Kevin R,et al.Overview of Pediatric Nonalcoholic Fatty Liver Disease:A Guide for General Practitioners Okla State Med Assoc[J].J Okla State Med Assoc,2018,111(8):806-811.[4]Doycheva I,Issa D,Watt KD,et al.Nonalcoholic Steatohepatitis is the Most Rapidly Increasing Indication for Liver Transplantation in Young Adults in the United States[J].Clin Gastroenterol,2008(52):339-346.[5]European Association for the Study of the Liver (EASL);European Association for the Study of Diabetes (EASD);European Association for the Study of Obesity (EASO).EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J].Diabetologia,2016,59(6):1121-1140. [6]Koopman N,Molinaro A,Nieuwdorp M,et al.Review article:can bugs be drugs?The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease[J].Aliment Pharmacol Ther,2019,50(6):628-639. [7]Gaggini M,Morelli M,Buzzigoli E,et al.Non-Alcoholic Fatty Liver Disease(NAFLD)and Its Connection with Insulin Resistance,Dyslipidemia,Atherosclerosis and Coronary Heart Disease[J].Nutrients,2013,5(5):1544-1560.[8]Higgins J.Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1.The Cochrane Collaboration[J].Naunyn Schmiedebergs Archiv Für Experimentelle Pathologie Und Pharmakologie,2008,5(2):S38.[9]Belfort R,Harrison SA,Brown K,et al.A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis[J].N Engl J Med,2006,355(22):2297-2307.[10]Balas B,Belfort R,Harrison SA,et al.Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis [J].Hepatol,2007,47(4):565-570.[11]Aithal GP,Thomas JA,Kaye PV,et al.Randomized,Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis[J].Gastroenterology,2008,135(4):1176-1184.[12]项岫秀,张慧芹,刘秀玲,等.吡格列酮对2型糖尿病合并非酒精性脂肪肝病患者血浆同型半胱氨酸水平的影响[J].临床荟萃,2009,24(15):1349-1350.[13]Sanyal AJ,Chalasani N,Kowdley KV,et al.Pioglitazone,Vit.Amin E,or Placebo for Nonalcoholic Steatohepatitis[J].N Engl J Med,2010,362(18):1675-1685.[14]徐园园,纪易斐.吡格列酮对糖尿病合并非酒精性脂肪肝炎的疗效观察[J].中华全科医学,2011,9(6):895,916.[15]呙劲松,陈艳.吡格列酮对糖耐量异常合并非酒精性脂肪肝患者血浆瘦素水平及胰岛素抵抗的影响[J].中南医学科学杂志,2014(4):379-381.[16]Cusi K,Orsak B,Bril F,et al.Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus:A Randomized Trial[J].Ann Intern Med,2016,165(5):305-315.[17]熊玮,唐淑亚,唐顺利.吡格列酮治疗非酒精性脂肪肝的疗效分析[J].中国社区医师,2018,34(22):65,67.[18]Anushiravani A,Haddadi N,Pourfarmanbar M,et al.Treatment options for nonalcoholic fatty liver disease:a double-blinded randomized placebo-controlled trial[J].Eur J Gastroenterol Hepatol,2019,31(5):613-617.[19]Younossi ZM.Non-alcoholic fatty liver disease--a global public health perspective[J].Hepatol,2019,70(3):531-544.[20]Hardy T,Oakley F,Anstee QM,et al.Nonalcoholic fatty liver disease:pathogenesis and disease spectrum[J].Annu Rev Pathol Mech Dis,2016(11):451-496.[21]Ekstedt M,Nasr P,Kechagias S.Natural History of NAFLD[J].Curr Hepatol Rep,2017,16(4):391-397.[22]Marchesini G,Brizi M,Bianchi G,et al.Nonalcoholic fatty liver disease:a feature of the metabolic syndrome[J].Diabetes,2001,50(8):1844-1850.[23]Saadati S,Sadeghi A,Mansour A,et al.Curcumin and inflammation in non-alcoholic fatty liver disease:a randomized,placebo controlled clinical trial[J].BMC Gastroenterol,2019,19(1):133.[24]Takao T,Kumagai C,Hisakawa N,et al.Effect of 17beta-estradiol on tumor necrosis factor-alpha-induced cytotoxicity in the human peripheral T lymphocytes[J].J Endocfinol,2005,184(1):191-197.[25]Miyazaki Y,Mahankali A,Matsuda M,et al.Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic Patines[J].Clin Endocrinol Metab,200,87(6):2784-2791.

相似文献/References:

[1]谢雨萌,毛乾国.非酒精性脂肪肝患者中医体质及相关证型研究[J].医学信息,2018,31(07):46.[doi:10.3969/j.issn.1006-1959.2018.07.016]
 XIE Yu-meng,MAO Qian-guo.Study on TCM Constitution and Correlative Syndromes of Nonalcoholic Fatty Liver Patients[J].Medical Information,2018,31(13):46.[doi:10.3969/j.issn.1006-1959.2018.07.016]
[2]刘 瑜,王 星,代 萌,等.2型糖尿病合并非酒精性脂肪肝的危险因素研究[J].医学信息,2018,31(23):108.[doi:10.3969/j.issn.1006-1959.2018.23.029]
 LIU Yu,WANG Xing,DAI Meng,et al.Study on Risk Factors of Type 2 Diabetes Mellitus with Non-alcoholic Fatty liver Disease[J].Medical Information,2018,31(13):108.[doi:10.3969/j.issn.1006-1959.2018.23.029]
[3]蒙春越.格列美脲联合吡格列酮治疗老年2型糖尿病合并 高血压患者的疗效分析[J].医学信息,2019,32(13):84.[doi:10.3969/j.issn.1006-1959.2019.13.023]
 MENG Chun-yue.Efficacy Analysis of Glimepiride Combined with Pioglitazone in the Treatment of Elderly Patients with Type 2 Diabetes Mellitus Complicated with Hypertension[J].Medical Information,2019,32(13):84.[doi:10.3969/j.issn.1006-1959.2019.13.023]
[4]黄丽玲,吴春城,梁惠卿,等.血清标志物壳多糖酶3样蛋白1评价肝纤维化的研究[J].医学信息,2021,34(10):32.[doi:10.3969/j.issn.1006-1959.2021.10.009]
 HUANG Li-ling,WU Chun-cheng,LIANG Hui-qing,et al.Serum Marker Chitinase 3-like Protein 1 in the Evaluation of Liver Fibrosis[J].Medical Information,2021,34(13):32.[doi:10.3969/j.issn.1006-1959.2021.10.009]
[5]郭月欢,甘惠中.幽门螺旋杆菌感染与非酒精性脂肪肝的相关性研究[J].医学信息,2022,35(08):89.[doi:10.3969/j.issn.1006-1959.2022.08.021]
 GUO Yue-huan,GAN Hui-zhong.Correlation Between Helicobacter Pylori Infection and Nonalcoholic Fatty Liver Disease[J].Medical Information,2022,35(13):89.[doi:10.3969/j.issn.1006-1959.2022.08.021]
[6]秦 莉,邱秀霞.肝病降脂颗粒对非酒精性脂肪肝患者肝脏生化及血脂水平的影响[J].医学信息,2022,35(21):65.[doi:10.3969/j.issn.1006-1959.2022.21.014]
 QIN Li,QIU Xiu-xia.Effect of Ganbing Jiangzhi Granules on Liver Biochemistry and Blood Lipid Levels in Patients with Nonalcoholic Fatty Liver Disease[J].Medical Information,2022,35(13):65.[doi:10.3969/j.issn.1006-1959.2022.21.014]
[7]陈 超,陈冯梅.血清尿酸/肌酐比值与老年人非酒精性脂肪肝的相关性研究[J].医学信息,2023,36(19):71.[doi:10.3969/j.issn.1006-1959.2023.19.014]
 CHEN Chao,CHEN Feng-mei.Correlation Between Serum Uric Acid/Creatinine Ratio and Nonalcoholic Fatty Liver Disease in the Elderly[J].Medical Information,2023,36(13):71.[doi:10.3969/j.issn.1006-1959.2023.19.014]
[8]王 晶,曹名波.非酒精性脂肪肝相关基因多态性的研究进展[J].医学信息,2023,36(24):183.[doi:10.3969/j.issn.1006-1959.2023.24.043]
 WANG Jing,CAO Ming-bo.Research Progress on Gene Polymorphisms Related to Non-alcoholic Fatty Liver Disease[J].Medical Information,2023,36(13):183.[doi:10.3969/j.issn.1006-1959.2023.24.043]

更新日期/Last Update: 1900-01-01